Compare PAYC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYC | PTGX |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.4B |
| IPO Year | 2014 | 2016 |
| Metric | PAYC | PTGX |
|---|---|---|
| Price | $123.57 | $114.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $168.79 | $108.23 |
| AVG Volume (30 Days) | ★ 840.1K | 612.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.04 | 0.05 |
| Revenue | ★ $433,047,000.00 | N/A |
| Revenue This Year | $8.79 | $874.25 |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | ★ $41.08 | $2,257.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $104.90 | $49.86 |
| 52 Week High | $248.95 | $114.49 |
| Indicator | PAYC | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 38.42 | 66.80 |
| Support Level | $118.80 | $94.48 |
| Resistance Level | $126.91 | N/A |
| Average True Range (ATR) | 5.31 | 4.72 |
| MACD | -1.86 | 1.46 |
| Stochastic Oscillator | 15.00 | 100.00 |
Paycom is a cloud-based human capital management provider offering payroll, compliance, and human resources management solutions. The firm's solutions are available on a unified, modular platform, and customers are billed for access on a subscription basis. Paycom's customer base skews toward the midmarket and is primarily based in North America. As of 2025, the firm manages records for 7.4 million employees across more than 20,000 clients on a parent-company-group basis.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.